Bausch Health Companies stock (CA0717341071): Canadian pharma name in focus after fresh institutional buying

Bausch Health Companies shares on the Toronto Stock Exchange traded around CAD 7.40 at the end of May 2026, while a new filing highlights that Hillsdale Investment Management has built a stake, putting the Canada-based specialty pharmaceutical group back on the radar of North American equity investors.

Bausch Health Companies, the Canada-based specialty pharmaceutical group listed on the Toronto Stock Exchange under the ticker BHC, remains in the spotlight after fresh institutional buying coincided with a subdued share price around CAD 7.41 at the close on 05/29/2026, according to MarketBeat as of 05/29/2026.MarketBeat as of 05/29/2026 The stock, which is also traded on the New York Stock Exchange in USD, opened at USD 5.37 on Monday, 06/01/2026, highlighting the cross-border interest in this Canadian healthcare issuer.MarketBeat as of 06/01/2026

According to a 06/01/2026 disclosure reported by MarketBeat, Hillsdale Investment Management Inc. disclosed the purchase of 524,892 shares of Bausch Health Cos Inc., underscoring that institutional investors in Canada continue to adjust their exposure to the stock as it trades closer to the lower half of its 52-week range between USD 4.41 and USD 8.69.MarketBeat as of 06/01/2026 In Germany, Bausch Health Companies is also accessible via Frankfurt and Tradegate under the symbol BVF, where it recently changed hands around EUR 4.38, offering an additional trading venue for European investors following the Canadian name.GuruFocus as of 05/2026

As of: 06/01/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Bausch Health Companies
• Sector/industry: Specialty pharmaceuticals and medical devices
• Headquarters/country: Laval, Canada
• Core markets: North America, Europe and selected international markets
• Key revenue drivers: Branded pharmaceuticals, eye health products via Bausch + Lomb, and gastroenterology therapies
• Home exchange/listing venue: Toronto Stock Exchange (BHC)
• Trading currency: CAD

Bausch Health Companies: core business model

Bausch Health Companies positions itself as a diversified healthcare player that focuses on branded pharmaceuticals and eye health offerings, with revenue shaped largely by prescription drugs, medical devices, and consumer health products sold across Canada, the United States, and other international regions.

What banks and research houses say about Bausch Health Companies

On the research side, the stock is still followed by a mix of Canadian and international analysts, with MarketBeat indicating as of 05/29/2026 that Bausch Health Companies carries an average rating of "Reduce" and a consensus price target of USD 8.00, reflecting a cautious stance despite some upside versus the latest New York trading levels around USD 5.37.MarketBeat as of 05/29/2026 This consensus view shows that while the Street is not broadly constructive, analysts still see room for the company to re-rate if it can execute on its strategic priorities and manage its leveraged balance sheet.

In a separate snapshot, MarketBeat notes in its 06/01/2026 institutional filing coverage that the same consensus and rating backdrop applies as investors digest the Hillsdale Investment Management stake disclosure, highlighting that institutional flows and sell-side estimates are evolving in parallel as the Canadian group navigates its current 52-week trading range between USD 4.41 and USD 8.69.MarketBeat as of 06/01/2026

Conclusion

The latest Hillsdale Investment Management stake disclosure offers a fresh data point for investors tracking Bausch Health Companies, complementing the muted share performance on the Toronto Stock Exchange and New York Stock Exchange at the end of May 2026. The consensus "Reduce" rating and USD 8.00 average price target reported by MarketBeat underline a cautious but not dismissive stance from analysts at a time when the stock is trading meaningfully below that level. Against this backdrop, the Canadian healthcare group remains a closely watched name as institutional flows, balance sheet considerations, and execution on its branded pharma and eye health portfolio continue to shape sentiment.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.